Regular flights from Port Harcourt to the Nnamdi Azikiwe Airport in Abuja will depart at 3:00 pm daily while flights from Abuja to Port Harcourt will depart at 4:30 pm every day.
Head Corporate Communications of the airline, Achilleus-Chud Uchegbu, in a statement disclosed that United Nigeria will also operate regular flights from Port Harcourt to Lagos every day at 6:00 pm.
This will remain a regular schedule of United Nigeria Airlines on the Port Harcourt route, he stated.
Vifor Pharma
Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™ injection in hemodialysis patients with moderate-to-severe pruritus
Monday, March 8, 2021 1:10PM IST (7:40AM GMT)
St. Gallen, Switzerland & Stamford, Conn., United States:
FDA has set Prescription Drug User Fee Act (PDUFA) target action date of 23 August 2021
If approved, KORSUVA™ injection would be first therapy for treatment of pruritus in hemodialysis patients
Regulatory News:
Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA™ (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA™ is 23 August 2021. The FDA stated that
Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA injection in hemodialysis patients with moderate-to-severe pruritus
If approved, KORSUVA injection would be first therapy for treatment of pruritus in hemodialysis patients
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210307005039/en/
Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA is 23 August 2021. The FDA stated that currently it is not planning to hold an advisory committee meeting to discuss the application.
(2)
Proof of concept for automated Fire Monkey High Molecular Weight (HMW) DNA extraction/size selection process in multi-well filter plate format validated by sequencing
Hands-free automated protocol on a bespoke Tecan Fluent 780 robotic liquid handler integrated with a Rotanda 460 robotic centrifuge
Extraction produces library-ready homogenous, long-length DNA (average 106kb) for short- and long-read DNA sequencing
Resultant sequence quality equivalent to manually-extracted DNA: >30Gb at N50 longer than 30kb
Automated DNA extraction enables further growth in high-throughput DNA sequencing applications with estimated market to >$50bn over the next 10 years
The UK genomic tools developer, RevoluGen Ltd. (RevoluGen or the Company), today announces the technology validation of the world s first automated extraction of library-ready High Molecular Weight (HMW) DNA in a multi-well filter plate format.